Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Treprostinil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 12/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 3/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 3/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 2/20 | 1.00 |
| ▸ | PTGFR | P43088 | 6/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Treprostinil SCHEMBL11914201 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL4349622 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL9418778 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL14732787 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL11953002 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL24243789 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL4349627 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL22282429 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL21530472 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR | |
| Treprostinil SCHEMBL16342147 | 1.00 | PTGIR (1.00) | PTGIRPTGER2PTGER1PTGDRPTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 609 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102610-B2 | Treprostinil salt | ELI LILLY AND COMPANY (US) | 2024-10-01 | — | — | US | claimed |
| CN-112739679-B | Terbutamine salt of treprostinil | 伊莱利利公司 | 2024-03-12 | — | — | CN | claimed |
| EP-3853200-B1 | ERBUMINE SALT OF TREPROSTINIL | LILLY CO ELI (US) | 2024-01-24 | — | — | EP | claimed |
| CN-116510005-A | Combined medicine for treating tumor | 正大天晴药业集团股份有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-114605497-B | Artificial small interfering peptide of DAPK1 phosphorylated substrate and pharmaceutical application thereof | 北京欣安诚科技有限公司 | 2023-04-28 | — | — | CN | claimed |
| EP-3512495-B1 | PROSTACYCLIN ANALOGUE FORMULATIONS | CAMURUS AB (SE) | 2022-11-09 | — | — | EP | claimed |
| CN-111405895-B | Controlled release pharmaceutical composition and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-109715138-B | Prostacyclin analogue formulations | 卡姆拉斯公司 | 2022-06-28 | — | — | CN | claimed |
| US-20220047535-A1 | Novel Treprostinil Salt | ELI LILLY AND COMPANY | 2022-02-17 | — | — | US | claimed |
| US-20150126589-A1 | Pulmonary Delivery of Messenger RNA | ETHRIS GMBH (DE) | 2015-05-07 | — | — | US | claimed |
| JP-6087749-A | — | — | None | — | — | JP | disclosed |
| US-20260041656-A1 | TREATING PULMONARY HYPERTENSION BASED ON NOVEL BIOMARKER | UNITED THERAPEUTICS CORPORATION (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4651879-A1 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | United Therapeutics Corporation (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250332175-A1 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | LIQUIDIA TECHNOLOGIES, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250319097-A1 | PROSTACYCLIN ANALOGUE FORMULATIONS | CAMURUS AB (SE) | 2025-10-16 | — | — | US | disclosed |
| US-20070078095-A1 | Vasodialtion; anticoagulants; angiogenesis inhibitors; oral bioavailability | UNITED THERAPEUTICS CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-7199157-B2 | Use of treprostinil to improve kidney functions | UNITED THERAPEUTICS CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199157-B2 | Use of treprostinil to improve kidney functions | UNITED THERAPEUTICS CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| JP-H0687749-A | PROSTAGLANDIN ANALOGUE FOR USE IN MEDICINE | WELLCOME FOUND LTD:THE | 1994-03-29 | — | — | JP | disclosed |
| US-5234953-A | 9-Deoxy-2'9-methano-3-oxa-4,5,6-trinor-3,7'-(1'3-inter-phenylene) -13,14-dihydroprostaglandin F1; vasodilation | BURROUGHS WELLCOME CO. (US) | 1993-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319097-A1 | PROSTACYCLIN ANALOGUE FORMULATIONS | PTGER1, PTGIS, PTGIR | PTGIR 3/4885PTGER2 8/4885PTGER1 1/4885 |
| US-20220047535-A1 | Novel Treprostinil Salt | TREH, DCTPP1, THPO | PTGIR 31/4885PTGER2 166/4885PTGER1 70/4885 |
| US-20070078095-A1 | Vasodialtion; anticoagulants; angiogenesis inhibitors; oral bioavailability | PTGIS, PTGIR, PLAT | PTGIR 2/4885PTGER2 74/4885PTGER1 38/4885 |
| US-20250332175-A1 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | PTGIR, PTGIS, TSLP | PTGIR 1/4885PTGER2 4/4885PTGER1 7/4885 |
| US-12102610-B2 | Treprostinil salt | TREH, DCTPP1, THPO | PTGIR 13/4885PTGER2 79/4885PTGER1 31/4885 |
| US-20260041656-A1 | TREATING PULMONARY HYPERTENSION BASED ON NOVEL BIOMARKER | KLHL6, IGFBP6, MYL6 | PTGIR 704/4885PTGER2 2319/4885PTGER1 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.